NCI RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Methods Mol Biol. 2024;2797:1-12. doi: 10.1007/978-1-0716-3822-4_1.
RAS research has entered the world of translational and clinical science. Progress has been based on our appreciation of the role of RAS mutations in different types of cancer and the effects of these mutations on the biochemical, structural, and biophysical properties of the RAS proteins themselves, particularly KRAS, on which most attention has been focused. This knowledge base, while still growing, has enabled creative chemical approaches to targeting KRAS directly. Our understanding of RAS signaling pathways in normal and cancer cells plays an important role for developing RAS inhibitors but also continues to reveal new approaches to targeting RAS through disruption of signaling complexes and downstream pathways.
RAS 研究已经进入转化和临床科学领域。这一进展基于我们对 RAS 突变在不同类型癌症中的作用以及这些突变对 RAS 蛋白本身（尤其是 KRAS）生化、结构和生物物理特性的影响的认识，而 KRAS 一直是关注的焦点。尽管这一知识库仍在不断发展，但它已经为直接针对 KRAS 的创造性化学方法奠定了基础。我们对正常细胞和癌细胞中 RAS 信号通路的理解不仅为开发 RAS 抑制剂发挥了重要作用，而且还不断揭示通过破坏信号复合物和下游途径来靶向 RAS 的新方法。
